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<ABSTRACT> 
PAUF is overexpressed in pancreatic cancer stem cells and confers 
chemoresistance. 
 
Jae Hee Cho 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Si Young Song) 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive 
malignancies. Similar to other tumors, pancreatic cancer stem cells (CSCs) have 
also been identified, and play an important role in development, maintenance, 
and metastasis of PDAC. Novel secretory protein of pancreatic adenocarcinoma 
up-regulated factor (PAUF) has been shown to contribute to cancer progression 
and metastasis. Because the clinical relationship between PAUF and pancreatic 
CSCs is largely unknown, we investigated the association between the 
functional role of PAUF and pancreatic CSCs. CFPAC-1 cancer spheres were 
cultured under nonadherent conditions with serum free media. PDAC spheres 
showed an elevated expression of PAUF protein and pluripotent stemness genes 
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(Oct4, Nanog, Stat3, and Sox2). The mRNA expression of PAUF was also 
upregulated in CD44+CD24+ESA+ pancreatic CSCs. Sphere formation and soft 
agar assays showed diminished number of spheres and colonies by PAUF 
knockdown (shPAUF) in CFPAC-1 cells. Expression of stemness genes and 
CSC surface markers (CD133, c-MET and ALDH1) were also lower in shPAUF 
CFPAC-1 cells than in normal control cells. MTT assay revealed that PAUF 
silent (siPAUF) CFPAC-1 cells had lower mRNA expression of multidrug 
resistant protein 5 (MRP5) and ribonucleotide reductase M2 (RRM2) and were 
more vulnerable to gemcitabine and 5-FU than negative control cells (p<0.05). 
In conclusion, PAUF is a novel human pancreatic CSC-associated protein that 
may confer chemoresistance by modulating MRP5 and RRM2. Thus, PAUF 
may constitute a therapeutic target for overcoming drug-resistant pancreatic 
CSCs. 
 
 
 
 
 
 
---------------------------------------------------------------------------------------------------------- 
Key words: cancer stem cells, PAUF, pancreatic cancer, MRP5, RRM2 
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PAUF is overexpressed in pancreatic cancer stem cells and confers 
chemoresistance. 
 
Jae Hee Cho 
 
Department of Medicine 
The Graduate School, Yonsei University  
(Directed by Professor Si Young Song) 
 
I. INTRODUCTION 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive 
malignancies and is the fourth leading cause of cancer-related death in the 
western world.1,2 The difficulty in early detection of PDAC and its resistance to 
conventional treatment options contribute to its dismal prognosis, as indicated 
by an overall 5-year survival rate of less than 10%.1,2 Many researchers have 
attempted to elucidate the pathogenesis and carcinogenesis of PDAC. However, 
the molecular basis for the aggressive nature of PDAC is incompletely 
understood, and the overall survival of patients has not improved significantly 
despite advances in treatment modalities and introduction of novel targeted 
therapies. 
The clinical outcomes of PDAC may be poor because conventional therapies 
are directed at tumor cells that have limited tumorigenic potential instead of 
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targeting the pancreatic cancer stem cells (CSCs) that have been identified in 
human PDAC.3 Pancreatic CSCs are identified by a variety of biomarkers, and 
transplantation assays using immune-deficient mice show that pancreatic CSCs 
self-renew and propagate the parental tumor. Li et al. has identified populations 
of CSCs in PDAC that express the cell surface markers CD44+CD24+ESA+ or 
c-Met.3,4 Apart from these markers, CD133+ and ALDH1 are regarded as other 
markers of CSCs in PDAC.5-7 These CSCs are also characterized by their 
chemoresistance, as CD133+ pancreatic cancer cells have greater drug resistance 
to gemcitabine,6 and c-MET inhibitors have been shown to enhance antitumor 
effects in combination with gemcitabine.3  
   Genome-wide analyses have uncovered pancreatic adenocarcinoma 
up-regulated factor (PAUF), a novel secretory protein associated with pancreatic 
cancer.8 Although the mechanism through which PAUF contributes to cancer 
progression is not clearly established, previous reports suggest it plays critical 
roles in PDAC progression and metastasis processes, including cell proliferation 
and modulation of adhesion, migration, and invasion. 9-15  
No studies have investigated the association between PAUF and CSCs and 
how it may contribute to drug resistance. Therefore, the purpose of the present 
study was to investigate the relationship between PAUF function and pancreatic 
CSCs. Our experiments provided evidence of PAUF expression in pancreatic 
CSCs and suggested that PAUF contributes to multi-drug resistance in the 
pancreatic CSCs 
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II. MATERIALS AND METHODS 
 
1. Clinical samples and cell lines 
Pancreatic cancer samples were obtained from surgical specimens at Myongji 
Hospital, Kwandong University of College of Medicine. Nine samples were 
obtained from pancreatic cancer resections, five from chronic pancreatitis 
resections, and eight from normal pancreas tissues obtained from benign 
pancreatectomy. The Ethics Committee for the Clinical Research of the 
Institutional Review Board of Myongji Hospital approved this study protocol.  
Eight PDAC cell lines (AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, 
HPAC, MiaPaca-2, and Panc-1) were obtained from ATCC(American Type 
Culture Collection). All cells were grown in the appropriate conditioned 
medium and maintained in an atmosphere of 5% CO2/95% air at 37˚C. We 
primarily used CFPAC-1, which expresses high endogenous levels of PAUF, for 
our experiments. 
 
2. Sphere culture 
For formation of spheres, single cells were cultured for 7 days in Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture 12 (DMEM/F12) containing 0.5% 
fetal bovine serum (FBS) (Hyclone), 0.5% bovine serum albumin fraction V 
(Gibco), insulin-transferrin-selenium A (Gibco), 10 ng/ml human epidermal 
growth factor (hEGF; R&D systems, Wiesbaden-Nordenstadt, Germany), 10 
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ng/ml human fibroblast growth factor (hFGF; R&D), and 10 ng/ml human 
leukemia inhibitory factor (hLIF; R&D) at a density of 1×103 cells/ml in an 
ultralow attachment plate (Corning, Corning, NY, USA). Growth factors were 
added every 3 days. For preparation of secretory proteins, culture medium was 
changed to serum-free medium in the post sphere culture after 5 days and 
cultured for an additional 2 days. 
 
3. Semi-quantitative PCR (reverse transcription PCR) 
The total RNA from cancer cells was extracted using a RNA easy extraction 
kit (Qiagen) according to the manufacturer’s instructions. To quantify the 
relative expression of the genes, we used β-actin primer as a control. The PCR 
primers used were PAUF sense, 5’-CACCTGGGCAGGGAAGATGTA-3’; 
PAUF antisense, 5’-GCTCAGTGGTCGGCTCCTCT-3’; β-actin sense, 
5’-GGCATCCTCACCCTGAAGTA –3’; and β-actin antisense, 
5’-GGGGTGTTGAAGGTCTCAAA-3’. The PCR primer sequences for the 
expression of genes related to pancreatic CSCs are described in Table 1.  
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Table 1. The sequences of PCR primer for the expression of known pancreatic 
CSCs related molecules 
Name Sequence 
ß-catenin (sense) GTATGAGTGGGAACAGGGATTT 
ß-catenin (antisense) CCTGGTCCTCGTCATTTAGC 
SOX2 (sense) CACAACTCGGAGATCAGCAA 
SOX2 (antisense) GTTCATGTGCGCGTAACTGT 
LEF1 (sense) CGAAGAGGAAGGCGATTTAG 
LEF1 (antisense) GGATGGGTGGAGAAAGAGAT 
WNT4 (sense) TTGAGGAGTGCCAGTACCAG 
WNT4 (antisense) CGTAGGCGATGTTGTCAGAG 
NANOG (sense) ACTGTCTCTCCTCTTCCTTCCT 
NANOG (antisense) AGAGTAAAGGCTGGGGTAGGTA 
IHH (sense) CCTGAACTCGCTGGCTATCT 
IHH (antisense) AATACACCCAGTCAAAGCCG 
JAGGED1 (sense) CTCAATTACTGTGGGACTCA 
JAGGED1 (antisense) GAACACTCACACTCAAAGCC 
GLI-1 (sense) CCTACCAGAGTCCCAAGTTT 
GLI-1 (antisense) AGAGTCCAGGGGGTTACATA 
NOTCH3 (sense) ATGGTGGGAACTAAACACAGCT 
NOTCH3 (antisense) ATGACCCTGGAGGAAGCACA 
PTCH (sense) CTCGGATTGGTGACCATAAG 
PTCH (antisense) GCSGTGGTGAGAGAAAAGGA 
DVL2 (sense) GGTTGGGGAGACGAAGGTGATT 
DVL2 (antisense) ATCTGAGGACACCAGCCAGGATAC 
HES1 (sense) GTGCTGTCTGGATGCGGAGT 
HES1 (antisense) ATTCCTGCTCTCGCCTTCG 
OCT4 (sense) AAG TGG GTG GAG GAA GCT 
OCT4 (antisense) CGA GGA GTA CAG TGC AGT 
STAT3 (sense) GTCTGGCTGGACAATATCAT 
STAT3 (antisense) TTGGGAATGTCAGGATAGAG 
CD44 (sense) CACCATTTCAACCACACCAC 
CD44 (antisense) GGTGTTGTCCTTCCTTGCAT 
CD133 (sense) GCTCAGACTGGTAAATCCCC 
CD133 (antisense) GACTCGTTGCTGGTGAATTG 
c-MET (sense) CAA TGT GAG ATG TCT CCA GC 
c-MET (antisense) CCT TGT AGA TTG CAG GCA GA 
ALDH1A1 (sense) AGCAGGAGTGTTTACCAAAGA 
ALDH1A1 (antisense) CCCAGTTCTCTTCCATTTCCAG 
ABCG2 (sense) CAC TGA TCC TTC CAT CTT GT 
ABCG2 (antisense) TAT GAG TGG CTT ATC CTG CT 
VIMENTIN (sense) GAG AAC TTT GCC GTT GAA GC 
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VIMENTIN (antisense) GCT TCC TGT AGG TGG CAA TC 
N-CADHERIN (sense) ACAGTGGCCACCTACAAAGG 
N-CADHERIN (antisense) CCGAGATGGGGTTGATAATG 
E-CADHERIN (sense) TGC CCA GAA AAT GAA AAA GG 
E-CADHERIN (antisense) GTG TAT GTG GCA ATG CGT TC 
SNAIL (sense) AAG CTT CCA TGG CGC GCT CTT TCC TCG TCA GGA AGC CC 
SNAIL (antisense) GGA TCC TCA GCG GGG ACA TCC TGA GCA GCC GGA CTC TTG 
SLUG (sense) AGC GAA CTG GAC ACA CAT ACA 
SLUG (antisense) CTG AGC CAC TGT GGT CCT T 
 
 
4. Establishment of stable PAUF knockdown cell line using shRNA  
The shRNA-expressing plasmid targeting human PAUF and negative control 
plasmid were purchased from SABiosciences. The human PAUF shRNA 
sequence was 5’-ACACCAGCAAGGACCGCTATT -3’ and the control 
shRNA sequence 5’-GGAATCTCATTCGATGCATAC -3’. For shRNA 
transfection, CFPAC-1 cells were plated into 6-well plates at a density of 5×104 
cells/well the day before transfection. Transfection was performed using 
Lipofectamine2000 reagent according to manufacturer’s instructions, and stable 
knockdown clones were selected using neomycin 
 
5. Transient transfection of small interfering RNA (siRNA) targeted for 
PAUF 
The two sets of 25-nucleotide stealth RNAi-targeting PAUF were synthesized 
customarily by Invitrogen. Stealth RNAi duplexes, which have a similar GC 
content to that of the duplex siRNA obtained from Invitrogen, were used as 
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negative controls. Stealth RNAi-targeting PAUF were transfected into 
CFPAC-1 cells using Lipectamine™ RNAi Max transfection agent (Invitrogen) 
according to the manufacturer’s protocol. Cells were harvested 72 h 
post-transfection and subjected to total RNA extraction and a migration and 
invasion assay. Secreted protein was prepared from culture medium 48 h 
post-transfection. 
 
6. MTT assay 
After incubation at 37˚C overnight, cells were treated with various 
concentrations of gemcitabine or fluorouracil (5-FU) in complete growth media 
and incubated for 72 h at 37˚C. A 3-(4,5-dimenthelthiazol-2-ly)-2,5 
-diphenyltetrasolium bromide-based assay (absorbance 570 nm) was used to 
measure the number of metabolically active cells 
 
7. Flow cytometry and cell sorting  
Cultured cells were detached with accutase solution (Sigma-Aldrich, Inc., St. 
Louis, MO, USA) and washed in phosphate-buffered saline (PBS) containing 
0.5% FBS. Single cells were stained for 20 min on ice in the dark, washed twice 
in PBS containing 0.5% FBS, and fixed in 2% paraformaldehyde. Flow 
cytometry analysis was performed using a FACSCalibur system (BS 
Biosciences, San Jose, CA), and cell sorting was performed using FACSAria II 
(BD Immunocytochemistry System, Franklin Lakes, NJ). Antibodies against 
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CD24 (anti-CD24-PE, BD), CD44 (anti-CD44-APC, BD), and ESA 
(anti-ESA-FITC, BD) were used. FITC-mouse IgG2b, κ isotype control (BD), 
rat IgG1 κ isotype control FITC (eBioscience), PE-mouse IgG2a, κ isotype 
control (BD), and APC-mouse IgG2b, κ isotype control (BD) were used as 
controls.  
 
8. Protein extraction and western blot  
Cells were prepared in lysis buffer containing 50 mM HEPES (pH 7.2), 150 
mM NaCl, 25 mM beta-glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM 
EDTA, 1% NP-40, 1 mM sodium orthovanadate, 0.1 mM 
phenylmethanesulfonylfluoride (PMSF), and a protease inhibitor cocktail 
(Roche Diagnostics). For secretory protein preparation, culture medium was 
centrifuged and the cellular components and debris were discarded. Culture 
medium was concentrated by the addition of ice-cold acetone, and the 
precipitated protein was resuspended with lysis buffer. Proteins were separated 
on SDS-PAGE and transferred to 0.45-µm Immobilon P-transfer membrane 
(Millipore). Membrane was blocked in 5% (w/v) non-fat milk and probed with 
the following primary antibodies: anti-human PAUF antibody (2009 Cancer 
Science), Sox2 (Cell Signaling Technology), Oct4 (Cell Signaling Technology), 
Nanog (Cell Signaling Technology), aldehyde dehydrogenase (ALDH) (BD), 
Cdk6 (Santa Cruz), cyclin D3 (Santa Cruz), Snail (Cell Signaling Technology), 
slug (Cell Signaling Technology), twist (Cell Signaling Technology) and 
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glyceraldehyde phosphate dehydrogenase (GAPDH) (Santa Cruz). 
Immunoreactive material was then visualized using SuperSignal West Pico 
Chemiluminescence Substrate16 according to the manufacturer’s instructions. 
 
9. Immunohistochemistry 
Paraformalin-fixed paraffin-embedded tissue sections (3-5-µm thickness) 
were deparaffinized in xylene, rehydrated with a graded ethanol series 
(100-95-90-80-70-50-30%), and washed with PBS. Endogenous peroxidase was 
blocked by immersing the slide in 0.3% (v/v) hydrogen peroxide in methanol 
for 10 min at room temperature. Microwave antigen retrieval was performed in 
citrate buffer (0.01 M, pH 6.0). The sections were blocked by soaking in 10% 
(v/v) normal donkey serum for 1 h and incubated with anti-human PAUF 
primary antibody (1:600) overnight at 4˚C. The sections were incubated with 
EnVision/HPR, Rabbit/Mouse (DakoCytomation, CA, USA) and 
diaminobenzidine (DAB+) chromogen. The sections were counterstained with 
hematoxylin (Sigma-Aldrich, Inc., St. Louis, MO, USA), dehydrated, and 
mounted. 
 
10. Soft agar assay 
A suspension of 500 single cells containing 0.3% agar medium was overlaid 
on 0.6% agar medium in 24-well plates. Each well was covered with complete 
medium, and the plates were incubated for 4 weeks. Colonies were stained with 
12 
 
crystal violet and counted. Experiments were done in triplicate. 
 
11. Statistical analysis 
Mann-Whitney U test and independent t-test were used to compare cell 
survival between siPAUF and control groups. Statistical calculations were 
performed using SPSS (version 12.0 for Windows; SPSS, Inc., Chicago, IL, 
USA). Values of p < 0.05 were considered statistically significant. 
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III. RESULTS 
 
1. Expression of PAUF protein in human pancreatic cancer  
Immunohistochemistry was performed to investigate the relationship between 
PAUF expression and clinicopathological features of pancreatic cancer. PAUF 
was aberrantly expressed in the all of nine pancreatic cancer specimens, as 
shown by the high-intensity pattern of cytoplasmic staining. This pattern was 
not observed in the five chronic pancreatitis or eight normal pancreas specimens 
(Fig 1).  
 
(A)         (B) 
 
Figure 1. Validation of PAUF expression in pancreatic tissues. (A) pancreatic 
cancer and (B) normal pancreatic tissue were stained with anti-PAUF 
antibodies.  Pancreatic cancer showed positive cytoplasmic staining of PAUF, 
whereas normal pancreatic tissue showed negative staining of PAUF (×400).  
 
A B 
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2. Pancreatic cancer spheres cultured from human pancreatic cancer cell 
lines 
We used sphere culture to identify CSCs. This in vitro method involved 
culturing candidate pancreatic CSCs with serum-free media containing only 
EGF and bFGF under nonadherent conditions, and the resulting spheres 
indicated self-renewal consistent with a CSC phenotype. In this study, PDAC 
spheres cultured from the CFPAC-1 cell line showed upregulated expression of 
the pluripotent stemness genes Oct4, Nanog, Stat3, and Sox2 relative to 
adherent CFPAC-1 cells (Fig 2).  
 
 
Figure 2. Expression of pluripotent stemness genes in pancreatic cancer spheres 
formed from CFPAC-1 cells. RT-PCR showed that the overexpression of Oct4, 
Nanog, Stat3, and Sox2 genes in CFPAC-1 sphere compare to adherent cells. 
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3. PAUF overexpression in pancreatic CSCs 
Based on previous reports that identified the cell surface markers 
CD44+CD24+ESA+ in a CSC population of human PDAC, we sorted the 
CFPAC-1 cell line into CD44+CD24+ESA+ PDAC cells using 
fluorescence-activated cell sorting (FACS) and determined PAUF gene 
expression using RT-PCR. To confirm the relationship between PAUF and CSCs, 
we measured the mRNA expression of PAUF in CD44+CD24+ESA+ pancreatic 
CSCs and the protein content of PAUF in PDAC spheres using western blots. 
PAUF protein content was higher in CFPAC-1 spheres than in adherent cells. 
Additionally, PAUF mRNA and protein content was higher in 
CD44+CD24+ESA+ CFPAC-1 than in CD44-CD24-ESA- CFPAC-1 cells (Fig 3).  
 
(A)     (B) 
 
Figure 3. PAUF overexpression in pancreatic cancer stem cells. (A) 
Up-regulation of secretory PAUF was determined by western blot in 
pancreatic cancer spheres formed from pancreatic cancer cells. (B) RT-PCR 
demonstrated that the mRNA expression of PAUF was higher in 
CD24+/CD44+/ESA+ cells than in CD24-/CD44-/ESA- pancreatic cancer cells. 
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4. PAUF knockdown effect on pancreatic CSCs  
To further access the specific role of PAUF in pancreatic CSCs function, we 
knocked down PAUF expression using shRNA targeting regions of PAUF. The 
shPAUF CFPAC-1 cells showed reduced cell proliferation, migration, and 
wound healing ability. The effect of PAUF knockdown, determined using sphere 
formation and soft agar assay, showed that negative control CFPAC-1 formed 
spheres and that shPAUF CFPAC-1 cells had markedly diminished formation of 
spheres. Furthermore, the soft agar assay showed that the number of colonies 
formed was also lower in the shPAUF CFPAC-1 cells (Fig. 4).  
The mRNA and protein expression of pluripotent stemness genes in shPAUF 
CFPAC-1 was measured using RT-PCR and western blot, respectively. The 
expression of stemness-related genes (including Oct4, Nanog, and Sox2), CSC 
surface markers (such as CD133, c-Met, and ALDH1), and the 
epithelial-mesenchymal transition marker, β-catenin were lower in the shPAUF 
CFPAC-1 than in the normal CFPAC-1 cells. Protein expression of PAUF, Sox2, 
ALDH, cyclin D3 and twist were lower in shPAUF CFPAC-1 than in control 
cells (Fig 5).  
 
 
 
 
17 
 
(A) 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
Figure 4. Effect of PAUF knockdown on sphere- and colony-forming ability. 
(A) Sphere formation assays were performed in negative control and shPAUF 
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CFPAC-1 cells. Knockdown of PAUF expression reduced sphere-forming 
ability. (B) Soft agar assays demonstrated decreased number of colonies 
formed in shPAUF CFPAC-1 cells than in negative control cells. 
 (A)                                   (B) 
 
(C)  
 
 
 
 
Figure 5. Differential gene expression in PAUF knockdown CFPAC-1 cells. (A) 
Expression of pluripotent stemness genes in shPAUF CFPAC-1 cells was 
determined by RT-PCR. (B) Expression of cancer stem cell and 
epithelial-mesenchymal transition markers were determined by RT-PCR. (C) 
Cancer stem cell-related proteins were validated by western blot. 
19 
 
We used FACS to determine the expression of pancreatic CSC-related surface 
markers CD24/CD44/ESA in siPAUF CFPAC-1 cells. The siPAUF CFPAC-1 
cells had a relatively smaller proportion of CD44+CD24+ESA+ CFPAC-1 CSCs 
than the cells with normal PAUF expression. (Fig 6) 
 
(A)      
 
 
 
(B)  
         
 
 
Figure 6. PAUF knockdown effects on the expression of pancreatic cancer stem 
cell markers (CD24/CD44/ESA) in CFPAC-1 cells. FACS analysis was used 
to determine the expression of pancreatic cancer stem cell markers 
(CD24/CD44/ESA) in negative control CFPAC-1 (A) and siPAUF CFPAC-1 
cells (B).    
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5. Effects of PAUF on chemoresistance of pancreatic cancer cell lines 
Past studies have suggested that pancreatic CSCs are more resistant to 
anti-cancer chemotherapy agents such as gemcitabine and 5-FU. To determine 
the role of PAUF in chemoresistance, we performed cell survival assays to 
validate cytotoxic effects of 5-FU or gemcitabine against PAUF-associated 
pancreatic cancer. Two transient siPAUF RNAs were used for this experiment. 
Both siPAUF CFPAC-1 cell lines were more vulnerable to the two cytotoxic 
drugs than the control CFPAC-1. (p<0.05, Fig. 7) Furthermore, mRNA 
expression of multidrug resistant protein 5 (MRP5) and ribonucleotide 
reductase M2 (RRM2) was lower in siPAUF CFPAC-1 cells than in negative 
control cells (Fig 8).  
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(A) 
 
 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
 
Figure 7. PAUF knockdown effects on the cytotoxicity of 72 h inoculation with 
gemcitabine and 5FU in CFPAC-1 cells. MTT assay showed significantly 
increased antitumor effect of gemcitabine (A) and 5FU (B) in PAUF-silenced 
CFPAC-1 cells compared to negative control.  
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Figure 8. PAUF knockdown effects on the mRNA expression of drug 
transporters and enzymes. RT-PCR demonstrated mRNA expression of MRP5 
and RRM2 was lower in the siPAUF CFPAC-1 cells than in the negative 
control. 
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IV. DISCUSSION 
Recent studies have demonstrated the presence of pancreatic CSCs, which are 
capable of self-renewal and production of differentiated progeny, in PDAC. 
Although the isolation and culturing of pancreatic CSCs remains difficult, the 
role of CSCs in development, maintenance, and metastasis of PDAC is 
increasingly recognized. In this study, we cultured the pancreatic cancer cell 
line CFPAC-1 in serum-free media and obtained pancreatic cancer sphere cells, 
which had self-renewal capabilities. Relative to the adherent cells, PDAC 
spheres showed increased mRNA and protein expression of PAUF and the 
pluripotent stemness genes Oct4, Nanog, Sox2 and STAT3. Additionally, 
CD44+CD24+ESA+ pancreatic CSCs had increased mRNA expression of PAUF. 
We recently identified PAUF, (also known as a paralog of ZG16B), a novel 
27-kDa secretory protein highly expressed in human PDAC. 8 As an autocrine 
factor, PAUF is involved in altered migration, invasion, proliferation, and 
metastasis.9,11,17 PAUF also acts as a paracrine factor by causing stromal 
changes in the tumor microenvironment that promotes tumor evasion of the 
immune surveillance system.12 PAUF also modulates permeability of the 
endothelial cells and vasculature to promote tumor angiogenesis.18 Although 
only a few preclinical studies have investigated anti-PAUF monoclonal 
antibodies, PAUF-specific RNA aptamers (P12FR2), and adenoviral 
PAUF-targeting trans-splicing ribozymes (TSR) for PDAC, PAUF-targeted 
therapies may be an alternative approach for cancer treatment.10,14,15 The 
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above-mentioned studies suggest functional roles of PAUF in pancreatic cancer; 
however, little is known about the clinical relationship between PAUF and 
pancreatic CSCs. Therefore, we show the association between PAUF expression 
and characteristics of CSCs to determine the contribution of PAUF activity to 
chemoresistance in pancreatic CSCs,  
Of clinical importance, recent research suggests CSCs are resistant to 
conventional chemotherapy and radiation.4 Enhanced expression of 
ATP-binding cassette (ABC) family of transporters has been shown to be 
characteristic of side population cells with CSC features. These side population 
cells are more resistant to chemotherapeutic agents and may play a key role in 
tumor progression, recurrence, and metastasis.19,20 To identify the relationship 
between chemoresistance and the functional role of PAUF in this study, we 
conducted cytotoxic studies with gemcitabine and 5-FU in siPAUF CFPAC-1 
and negative control cells. Our study showed that siPAUF CFPAC-1 cells were 
significantly more vulnerable to both cytotoxic drugs. Because the 
chemoresistant mechanisms can occur through intracellular enzymes, uptake, 
and/or export drug transporters, we measured the mRNA expression of genes 
involved in drug metabolism (such as dCK, CDA, RRM1, and RRM2) and 
transporters (including MRP3, MRP4, MRP5, and hENT1). In the present study, 
the siPAUF CFPAC-1 cells had lower mRNA expression of MRP5 and RRM2. 
MRP5 (also known as ABCC5) is a member of the multidrug 
resistance-associated protein subfamily of ABC transporters and confers 
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resistance against chemotherapeutic drugs such as etoposide, 5-FU, and 
gemcitabine.21-23 RRM2 is the catalytic subunit of ribonucleotide reductase, a 
dimeric enzyme that supplies deoxynucleotides essential for DNA replication 
and cell growth. The overexpression of RRM2 has been associated with 
gemcitabine resistance and increased cellular invasiveness in vitro,24 25 and high 
expression of RRM2 in pancreatic tumors is associated with reduced overall 
survival after resection.26  
Taken together, our study indicated that PAUF signaling is required for the 
survival of pancreatic CSCs. In addition, PAUF may contribute to drug 
resistance through mechanisms involving MRP5 and RRM2, thus making it a 
novel target for treatment of PDAC. However, our study had some limitations. 
We used pancreatic cancer cell lines rather than patient-derived pancreatic 
cancer cells for many of our experiments and only investigated the effect of 
PAUF knockdown in PDAC cancer cell lines rather than in pancreatic CSCs 
derived from human tissues. In addition, we did not perform the experimental 
study using in vivo models of human PDAC, which are required to prove a 
causal relationship between PAUF and target proteins such as MRP5 and RRM2. 
Thus, the possible connection between PAUF, drug transporters, and cell 
signaling pathways should be investigated in future studies. 
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V. CONCLUSION 
In conclusion, we showed that PAUF is a novel protein in human pancreatic 
CSCs that may contribute to chemoresistance by modulating MRP5 and RRM2. 
Thus, PAUF may constitute a therapeutic target to reduce the drug resistance of 
pancreatic CSCs.  
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항암제 내성 증가와 연관된 PAUF 단백의   
   췌장암줄기세포 내 과발현 
<지도교수 송시영> 
 
연세대학교 대학원 의학과 
조재희 
 
췌장암은 예후가 불량한 암으로 서구에서는 암 연관 사망의 4번째 
원인이다. 췌장암줄기세포는 췌장암의 발생, 유지, 전이의 중요한 
역할을 하고 있는 것으로 알려져 있고, 최근 발견된 PAUF (pancreatic 
adenocarcinoma up-regulated factor) 단백은 암의 진행과 전이와 
연관됨이 보고되었다. 이에 저자 등은 췌장암줄기세포와 PAUF의 
연관성을 확인하고 작용 기전을 연구하고자 하였다.  
CFPAC-1 췌장암 세포주를 serum free media 의 nonadherent 환경에서 
췌장암 sphere로 배양하였고, Western blot과 RT-PCR 실험을 진행하여 
PAUF 단백과 Oct4, Nanog, Stat3, and Sox2 등의 줄기세포 연관 
mRNA의 과발현을 확인하였다. 또한 CFPAC-1 췌장암세포주를 FACS 
분석을 통해 췌장암줄기세포로 생각되는 CD44+CD24+ESA+ CFPAC-1로 
분리하고, PAUF mRNA의 과발현을 관찰하였다. 
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PAUF의 발현 억제와 암줄기세포의 연관성을 확인하기 위해 다음과 
같은 실험이 추가로 진행하였다. PAUF knockdown (shPAUF) CFPAC-1 
췌장암세포주에 대한 sphere formation과 soft agar assay 실험에서 
shPAUF CFPAC-1은 sphere 및 colony 형성이 모두 감소하였고, 
줄기세포 연관 유전자와 암줄기세포 표면 표시 인자(CD133, c-MET 
and ALDH1)의 mRNA가 감소되었다. PAUF silent (siPAUF) CFPAC-1 
세포주를 이용한 MTT 분석에서 Gemcitabine과 5-FU 항암제 감수성은 
PAUF를 억제하는 경우 증가하였으며, siPAUF CFPAC-1에서 
MRP5(multidrug resistant protein 5)와 RRM2(ribonucleotide reductase M2) 
mRNA의 발현 저하가 확인되었다. 
결론 하자면, PAUF 는 췌장암 줄기세포와 연관 단백질로, MRP5와 
RRM2의 발현을 조절하여 항암제 내성과 연관성이 있다. 그러므로, 
추후 PAUF는 췌장암줄기세포의 항암제내성 극복을 위한 표적 물질로 
사용이 기대된다.  
 
 
 
------------------------------------------------------------------------------------------------ 
핵심 되는 말: 암줄기세포, PAUF, 췌장암, MRP5, RRM2 
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ACRONYMS LIST 
 Pancreatic ductal adenocarcinoma: PDAC 
 Cancer stem cells: CSCs 
Pancreatic adenocarcinoma up-regulated factor: PAUF 
Octamer-binding transcription factor 4: Oct4 
Signal transducer and activator of transcription 3: Stat3 
Sex determining region Y-box 2: Sox2 
Epithelial-specific antigen: ESA 
Aldehyde dehydrogenase: ALDH 
Phosphatase and tensin homolog: PTEN 
Lymphoid enhancer-binding factor 1: Lef1 
Dishevelled segment polarity protein 2: Dvl2 
Multidrug resistant protein: MRP 
Ribonucleotide reductase M: RRM 
American Type Culture Collection: ATCC 
Human epidermal growth factor: hEGF; 
Human fibroblast growth factor: hFGF 
Human leukemia inhibitory factor: hLIF; 
Fluorescence-activated cell sorting: FACS 
Cyclin-dependent kinase 6: CDK6  
Deoxycytidine kinase: dCK 
Equilibrative nucleoside transporter 1: ENT1 
